Prasugrel Round Two: Is FDA Approval In Sight?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA action on Eli Lilly/Daiichi Sankyo’s clot buster anticipated Sept. 26.
You may also be interested in...
Lilly Prasugrel Review Extended: Why No News May Be Good News
Platelet drug deadline slips, but analysis by The RPM Report suggests that may be a sign of a positive outcome.
Lilly Prasugrel Review Extended: Why No News May Be Good News
Platelet drug deadline slips, but analysis by The RPM Report suggests that may be a sign of a positive outcome.
Prasugrel Could Avoid More Restrictive REMS Options, Lilly Hints
Should a risk management and evaluation strategy accompany approval of Lilly's anti-platelet drug prasugrel, the product may escape the most burdensome REMS options, Lilly hinted during its July 24 earning call